2,659 results match your criteria: "The Fourth Hospital of HeBei Medical University[Affiliation]"
Front Immunol
December 2024
Department of Emergency, Third Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Purpose: Sepsis is an unusual systemic reaction to what is sometimes an otherwise ordinary infection, and it probably represents a pattern of response by the immune system to injury. However, the relationship between biomarkers and sepsis remains unclear. This study aimed to find potential molecular biomarkers, which could do some help to patients with sepsis.
View Article and Find Full Text PDFChin Med J (Engl)
December 2024
Department of Gastrointestinal Surgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266000, China.
Background: Neoadjuvant chemoradiotherapy followed by radical surgery has been a common practice for patients with locally advanced rectal cancer, but the response rate varies among patients. This study aimed to develop a ResNet-Vision Transformer based magnetic resonance imaging (MRI)-endoscopy fusion model to precisely predict treatment response and provide personalized treatment.
Methods: In this multicenter study, 366 eligible patients who had undergone neoadjuvant chemoradiotherapy followed by radical surgery at eight Chinese tertiary hospitals between January 2017 and June 2024 were recruited, with 2928 pretreatment colonic endoscopic images and 366 pelvic MRI images.
Clin Lung Cancer
November 2024
Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China. Electronic address:
Background: Examination standards for hilar and intrapulmonary (N1) lymph nodes (LNs) have been debated. The objective of this study was to assess the prognostic significance of the extent of examination for N1 LN stations in patients with pathological stage I non-small cell lung cancer (NSCLC).
Methods: A total of 1868 patients were identified and divided into 3 groups on the basis of the number of N1 stations examined: group A (≥3 stations), group B (2 stations) and group C (1 station).
Hematol Oncol
January 2025
Department of Lymphoma, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, China.
Polatuzumab vedotin plus R-CHP (Pola-R-CHP) is approved as a new standard first-line therapy for diffuse large B-cell lymphoma (DLBCL) based on the POLARIX trial. However, real-world data on its efficacy and safety in unselected patients is lacking. We conducted a retrospective cohort study to evaluate Pola-R-CHP versus R-CHOP outcomes in routine clinical practice in China.
View Article and Find Full Text PDFViral Immunol
December 2024
Department of Infectious Disease, The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and first identified in Wuhan, China, in December 2019, has led to global efforts in vaccination to mitigate rising morbidity and mortality, with vaccines proving crucial in controlling the pandemic. This study evaluated the humoral responses to the inactivated virus vaccine Sinopharm or Koxing Kerlafor, the protein subunit vaccine ZF001, and the adenoviral vector vaccine Convidecia after 18 months of inactivated virus vaccination by heterologous and homologous booster vaccination in patients with previous SARS-CoV-2 infection and healthy individuals. We discovered that patients who had recovered from the infection and then received a third vaccine dose (booster) exhibited durable immunity.
View Article and Find Full Text PDFFront Pharmacol
November 2024
Department of Clinical Pharmacology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
A single-oral-dose, two-period cross-over study with a 5-day washout period under fed condition was conducted in six beagle dogs to explore the pharmacokinetic characteristics and relative bioavailability between sustained-release (SR) tablets and enteric-coated (EC) tablets of pentoxifylline (PTX) and its metabolite. The results showed that M5 exhibited the highest exposure level, while M1 demonstrated the lowest in both the SR and EC tablet groups. For PTX and M1, T were 0.
View Article and Find Full Text PDFClin Appl Thromb Hemost
December 2024
Department of Cardiology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei Provence, People's Republic of China.
J Stomatol Oral Maxillofac Surg
December 2024
Department of Stomatology, The Fourth Hospital of Hebei Medical University, PR China. Electronic address:
Adv Sci (Weinh)
December 2024
State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Hypoxia is a typical hallmark of solid tumors and plays a crucial role in the progression of esophageal squamous cell carcinogenesis (ESCC). Nevertheless, the precise mechanisms underlying the involvement of hypoxia in tumor development remain unclear. In the present study, a novel hypoxia-induced long noncoding RNA (lncRNA) is identified first, lnc191, which is highly expressed in clinical ESCC tissues and is positively correlated with poor prognosis of ESCC patients.
View Article and Find Full Text PDFFuture Oncol
December 2024
TopAlliance Biosciences, Rockville, MD, USA.
Br J Hosp Med (Lond)
November 2024
Neurology Department, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Gastric cancer is the third leading cause of cancer-related death worldwide, which seriously affects the health of patients. Immunotherapy is a commonly used clinical treatment for gastric cancer, but the adverse events caused by it seriously affect the prognosis of patients. Therefore, it is necessary to control and manage the disease risk of patients during immunotherapy.
View Article and Find Full Text PDFBMC Cancer
November 2024
Department of Breast Disease Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050000, China.
Backgrounds: To develop a machine learning (ML) model for predicting the prognosis of breast cancer (BC) patients with low human epidermal growth factor receptor 2 (HER2) expression, and to investigate the association between clinicopathological characteristics and outcomes in HER2-low BC (HLBC) patients.
Methods: A retrospective analysis was conducted on data from 998 female HLBC patients treated at the Breast Center of the Fourth Hospital of Hebei Medical University (Hebei, China) between January 1, 2017, and December 31, 2020. To address class imbalance, the synthetic minority over-sampling technique was applied.
Asian J Surg
November 2024
Department of Orthopedics, The Fourth Hospital of Hebei Medical University, Hebei Provincial Cancer Institute, Shijiazhuang, Hebei, China.
Cancer Med
December 2024
Cancer Institute in Hebei Province, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Objective: The purpose of this study was to analyze the effectiveness of the Cancer Screening Program in Urban China (CanSPUC) in Hebei Province, 2016-2023.
Methods: A questionnaire for risk factors of lung, breast, upper gastrointestinal, liver, and colorectal cancers was administered to urban residents aged 40-74 years in five cities to assess their cancer risk. High-risk participants were invited for screening and classified into five groups on the basis of the number of cancer types that were assessed to be high risk.
Front Oncol
November 2024
Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University (Hebei Tumor Hospital), Shijiazhuang, Hebei, China.
The debate continues whether the expression of the same rare genetic mutation in multiple primary lung cancers suggests intrapulmonary metastasis or truly multiple primary lung cancers. We report a case of a 54-year-old female patient who presented with multiple nodules in the right lung discovered during a routine examination, persisting for six months. The patient had three central lesions in the right lung's upper, middle, and lower lobes.
View Article and Find Full Text PDFInt J Clin Oncol
January 2025
The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050000, Hebei, China.
Discov Oncol
November 2024
Department of Pharmacy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17, Panjiayuan Nanli, Chaoyang, Beijing, 100021, China.
Objective: This study aimed to assess the safety and efficacy of generic nab-paclitaxel in the Chinese population in a real-world setting.
Methods: This prospective, multicenter, observational study enrolled patients with malignancies who received any generic nab-paclitaxel-based regimens in China. The primary endpoint was safety, and secondary endpoint was objective response rate (ORR).
Int J Womens Health
November 2024
Department of Gynecology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, 050011, People's Republic of China.
Background: Although both cervical intraepithelial neoplasia (CIN) II and CIN III carry the potential to progress into cervical cancer, to date, an optimal screening method for CIN2+ (CIN II, CIN III, and cervical cancer) cervical lesions is yet to be established.
Methods: In this retrospective study, data from 2035 patients treated at the Fourth Hospital of Hebei Medical University between 2019 and 2021 were analyzed. The screening efficacy of three methods-the ThinPrep cytologic test (TCT) alone, the high-risk-human papillomavirus (HR-HPV) test alone, and the combined TCT and HR-HPV screening for CIN2+ lesions-were assessed using cervical histopathology as the reference standard.
Open Life Sci
November 2024
Department of Urology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Clear cell renal cell carcinoma (ccRCC) is a challenging malignancy characterized by intricate biology and clinical characteristics. Despite advancements in treatment strategies, the molecular mechanisms underlying ccRCC initiation, progression, and therapeutic resistance remain elusive. Inflammasomes, multi-protein complexes involved in innate immunity and inflammation, have emerged as potential regulators in cancers.
View Article and Find Full Text PDFRadiat Oncol
November 2024
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Background: Accurate calculation of lung cancer dose using the Monte Carlo (MC) algorithm in CyberKnife (CK) is essential for precise planning. We aim to employ deep learning to directly predict the 3D dose distribution calculated by the MC algorithm, enabling rapid and accurate automatic planning. However, most current methods solely focus on conventional intensity-modulated radiation therapy and assume a consistent beam configuration across all patients.
View Article and Find Full Text PDFAsian J Surg
November 2024
Department of Orthopedics, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, Hebei, China. Electronic address:
Explore (NY)
November 2024
The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050000, China. Electronic address:
Int J Nanomedicine
November 2024
Department of Orthopaedic Surgery, Third Hospital of Hebei Medical University, Shijiazhuang, Hebei, People's Republic of China.
Introduction: Ferroptosis-driven tumor ablation strategies based on nanotechnology could be achieved by elevating intracellular iron levels or inhibiting glutathione peroxidase 4 (GPX4) activity. However, the intracellular antioxidative defense mechanisms endow tumor cells with ferroptosis resistance capacity. The purpose of this study was to develop a synergistic therapeutic platform to enhance the efficacy of ferroptosis-based tumor therapy.
View Article and Find Full Text PDFBreast Cancer Res Treat
November 2024
Department of Radiology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Haidian District, No. 52 Fucheng Road, Beijing, China.